BioSight
Companies
Cogent Biosciences, Inc. logo

COGT

NASDAQWALTHAM, MA
Cogent Biosciences, Inc.

Cogent Biosciences develops small-molecule drugs targeting kinase enzymes, with bezuclastinib as its lead program currently in clinical development. The company focuses on treating rare genetic disorders and other serious conditions where specific kinase mutations drive disease. Cogent is in the clinical-stage phase of development and depends heavily on bezuclastinib's success to advance its pipeline and achieve profitability.

Price history not yet available for COGT.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar